Dive into a collection of past posts and rediscover timeless content.
A landscape supply distributor with 90-plus acquisitions and a CEO who just wrote an $816K personal check is trading near a 52-week low while analysts see 30% upside. See if it makes sense.
A travel booking giant screens at roughly 50% upside, while most Westerners have not updated their view since 2022. Here's what they are missing.
A SaaS company beat Q2 by 30%, raised guidance, and just achieved GAAP profitability while growing its employee experience platform at the fastest rate in the business. Find out if it belongs in your portfolio.
This quarter, a neuroscience company files its lead seizure drug with the FDA. Analyst targets run to $100. Here's the setup before the paperwork lands.
A medical imaging leader beat Q2 earnings by 9%, hit a record $23.9 billion backlog, and is reviewing its weakest segment for a potential sale.
This chocolate stock got punished when cocoa exploded, but the biggest pressure on margins is finally easing. The valuation now looks far more interesting.
The company that built the digital infrastructure of an entire economy trades at a massive discount to peers, reports Q2 Monday, and yields nearly 8%. Find out if the setup is worth the country risk.
An energy drink name just reported into sentiment that had already gone flat, with the Street looking for nearly 18% growth. The reaction is the real signal here.
The company that builds the boards inside AI switches and defense radar systems reports Q2 results tomorrow. Four consecutive earnings beats behind it and 55% growth expected. See if it belongs in your portfolio.